lmp2 antigen-specific tcr t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2019 (NCT03925896)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Proteasome subunit beta type-9Immunity, passive
PSMB9 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04509726 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2020 | People's Liberation Army of China, TCRCure Biopharma Corp. |
| NCT03925896 | Phase 1 | May 1, 2019 | Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| TCRCure Biopharma Corp. | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1